TY - JOUR
T1 - A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans
AU - Veldhuis, Johannes D.
AU - Bidlingmaier, Martin
AU - Bailey, Joy
AU - Erickson, Dana
AU - Sandroni, Paola
N1 - Funding Information:
This work was supported in part via the Clinical Translational Research Center Grant MO1 RR00585 to the Mayo Clinic and Foundation from the National Center for Research Resources (Rockville, MD) and R01 NIA AG29362 and AG19596 from the National Institutes of Health (Bethesda, MD).
PY - 2010/8
Y1 - 2010/8
N2 - Background: GH receptors exist in the hippocampus, cerebral cortex, and hypothalamus, possibly influencing mood, cortical blood flow, and neuronal growth and mediating negative feedback. Rationale: Pegvisomant is a recombinant mutated GH molecule with high affinity, but little or no activating capability, for the GH receptor. It is used clinically as a GH antagonist. Hypothesis: Systemic pegvisomant enters brain interstitial fluid via putative choroid-plexus GH receptors, thereby allowing for antagonism of central actions of GH. Subjects and Location: Six adults requiring a cerebrospinal fluid (CSF) examination for nonneoplastic and noninflammatory syndromes participated at a tertiary medical center. Methods: Direct assays were conducted of serum and CSF pegvisomant concentrations 18-24 h after sc injection of pegvisomant (20 mg). Outcomes: Median (range) concentrations of pegvisomant in serum were 215 (74-539) μg/liter and in CSF 0.035 (0.010-0.28) μg/liter (P = 0.016). CSF drug levels were indistinguishable from assay threshold. Corresponding GH values were 0.29 (0.010-1.3) in serum and 0.075 μg/liter (0.01-0.13) in CSF. The geometric mean ratios of serum/CSF pegvisomant and GH concentrations were 5116:1 and 3.5:1, respectively, thus defining a more than 1400-fold difference between mutated and natural GH. Conclusions: Based upon CSF measurements, a pegylated GH-receptor antagonist does not cross the human blood-brain barrier, thereby sparing inhibition of central nervous system GH actions. Thus, the capability of this antagonist to stimulate GH secretion predominantly reflects its actions outside the blood-brain barrier, such as via the median eminence and/or via suppression of IGF-I concentrations.
AB - Background: GH receptors exist in the hippocampus, cerebral cortex, and hypothalamus, possibly influencing mood, cortical blood flow, and neuronal growth and mediating negative feedback. Rationale: Pegvisomant is a recombinant mutated GH molecule with high affinity, but little or no activating capability, for the GH receptor. It is used clinically as a GH antagonist. Hypothesis: Systemic pegvisomant enters brain interstitial fluid via putative choroid-plexus GH receptors, thereby allowing for antagonism of central actions of GH. Subjects and Location: Six adults requiring a cerebrospinal fluid (CSF) examination for nonneoplastic and noninflammatory syndromes participated at a tertiary medical center. Methods: Direct assays were conducted of serum and CSF pegvisomant concentrations 18-24 h after sc injection of pegvisomant (20 mg). Outcomes: Median (range) concentrations of pegvisomant in serum were 215 (74-539) μg/liter and in CSF 0.035 (0.010-0.28) μg/liter (P = 0.016). CSF drug levels were indistinguishable from assay threshold. Corresponding GH values were 0.29 (0.010-1.3) in serum and 0.075 μg/liter (0.01-0.13) in CSF. The geometric mean ratios of serum/CSF pegvisomant and GH concentrations were 5116:1 and 3.5:1, respectively, thus defining a more than 1400-fold difference between mutated and natural GH. Conclusions: Based upon CSF measurements, a pegylated GH-receptor antagonist does not cross the human blood-brain barrier, thereby sparing inhibition of central nervous system GH actions. Thus, the capability of this antagonist to stimulate GH secretion predominantly reflects its actions outside the blood-brain barrier, such as via the median eminence and/or via suppression of IGF-I concentrations.
UR - http://www.scopus.com/inward/record.url?scp=77955357712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955357712&partnerID=8YFLogxK
U2 - 10.1210/jc.2010-0538
DO - 10.1210/jc.2010-0538
M3 - Article
C2 - 20444908
AN - SCOPUS:77955357712
SN - 0021-972X
VL - 95
SP - 3844
EP - 3847
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -